Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 ...

Natural products are among the most promising candidates for the development of new drugs. However, due to their structural complexity, they are often difficult to access.